The acquisition will be financed by a cash payment of DKK 7.0 million as well as the assumption
of an existing mortgage loan of DKK 9.2 million. The purchase is conditional upon approval at
an extraordinary general meeting convened on August 5th, 2026, at which the board of directors
will propose both the acquisition itself and the financing of the cash payment through a capital
raise.
The company is still in process with various investments in order to continue to execute the
strategy to increase the company's investments in strategic partnerships with companies with
significant potential, as well as in other equity interests and real estate.
The result from property investments is realized at a net gain of DKK 0.1 million compared to
DKK 0.1 million for the same period in 2025.
The result from our strategic co-ownership in listed and unlisted companies is realized at a net
gain of DKK 1.9 million compared to DKK 0.0 million for the same period in 2025.
Diluted net asset value per share is DKK 465 on June 30th, 2026.
Management’s review and Business update
In continuation of the strategy, it is still the Company's wish to continue investing and adding
competences in new partnerships in order to create added value for the Company's
shareholders, as well as to attract additional capital to the company via capital raisings or the
purchase of companies/assets via the issue of new shares in order to gain a greater critical
mass.
Risk and uncertainties
For information on risks and uncertainties relating to Orphazyme’s business please refer to our
Statutory Annual Report 2025. Additional risks and uncertainties, including risks that are not
known to the Company at present or that its management currently deems immaterial or non-
specific to the Company, may also arise or become material or specific to the Company in the
future, which could, if such risks were to materialize, have a material and adverse effect on the
Company’s business, financial condition, and/or results of operations.
Page 2 of 11